<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <link href="/kxreader/Content/css/detail?v=NOOK-mvTMnxl11s6oPYV0boPXN3iP4N7Rc-A56nk4KI1" rel="stylesheet"/>

    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>
</head>

<body>
    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141082080443750%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dZGWT201904005%26RESULT%3d1%26SIGN%3dA7o%252b96kC6EbhZbNqLfu525Yr%252bUg%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=ZGWT201904005&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=ZGWT201904005&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>

    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZGWT201904005&amp;v=MTc1MzZZWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm5GeURtVWJ6TVB5cmNlckc0SDlqTXE0OUY=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#38" data-title="资料与方法 ">资料与方法</a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#39" data-title="1.研究对象">1.研究对象</a></li>
                                                <li><a href="#41" data-title="2.调查内容">2.调查内容</a></li>
                                                <li><a href="#43" data-title="3.数据整理及分析">3.数据整理及分析</a></li>
                                                <li><a href="#45" data-title="4.研究方法">4.研究方法</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#87" data-title="结  果 ">结  果</a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#92" data-title="讨  论 ">讨  论</a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#" data-title="文内图表 ">文内图表</a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#54" data-title="&lt;b&gt;图1&lt;/b&gt; 试验组和对照组患者的比较"><b>图1</b> 试验组和对照组患者的比较</a></li>
                                                <li><a href="#70" data-title="&lt;b&gt;表1&lt;/b&gt; 输赢指标变量图"><b>表1</b> 输赢指标变量图</a></li>
                                                <li><a href="#90" data-title="&lt;b&gt;图2&lt;/b&gt; 各变量生存曲线图"><b>图2</b> 各变量生存曲线图</a></li>
                                                <li><a href="#91" data-title="&lt;b&gt;表2&lt;/b&gt; GvHD预防临床益处的评估"><b>表2</b> GvHD预防临床益处的评估</a></li>
                                    </ul>
                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="4">


                                    <a id="bibliography_1" title=" Thomas ED,Sanders JE,Flournoy N,et al.Marrow transplantation for patients with acute lymphoblastic leukemia in remission.Blood,1979,54 (2):467." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Marrow transplantation for patients with acute lymphoblastic leukemia in remission">
                                        <b>[1]</b>
                                         Thomas ED,Sanders JE,Flournoy N,et al.Marrow transplantation for patients with acute lymphoblastic leukemia in remission.Blood,1979,54 (2):467.
                                    </a>
                                </li>
                                <li id="6">


                                    <a id="bibliography_2" title=" Moy&#233; LA.Introduction to Composite Endpoints.Publications of the American Statistical Association,2007,100 (472):1463." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Introduction to Composite Endpoints">
                                        <b>[2]</b>
                                         Moy&#233; LA.Introduction to Composite Endpoints.Publications of the American Statistical Association,2007,100 (472):1463.
                                    </a>
                                </li>
                                <li id="8">


                                    <a id="bibliography_3" title=" PavlovicM,Teljeur C,Wieseler B,et al.Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.International Journal of Technology Assessment in Health Care,2014,30 (5):508-513." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SCUD&amp;filename=SCUD15062400106572&amp;v=MjkwOTRiSUtGMFdhUlk9Tmk3ZWFySzlIdGZPcTQ5Rlplc0pDWHM3b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[3]</b>
                                         PavlovicM,Teljeur C,Wieseler B,et al.Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.International Journal of Technology Assessment in Health Care,2014,30 (5):508-513.
                                    </a>
                                </li>
                                <li id="10">


                                    <a id="bibliography_4" title=" Alosh M,Bretz F,Huque M.Advanced multiplicity adjustment methods in clinical trials.Statistics in Medicine,2014,33(4):693-713." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD14011600000546&amp;v=MTM5NDRhcks4SHRETnFZOUZaT3NQQ1hnL29CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJiSUtGMFdhUlk9TmlmYw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                         Alosh M,Bretz F,Huque M.Advanced multiplicity adjustment methods in clinical trials.Statistics in Medicine,2014,33(4):693-713.
                                    </a>
                                </li>
                                <li id="12">


                                    <a id="bibliography_5" title=" Manja V,Albashir S,Guyatt G.Criteria for use of Composite Endpoints for Competing Risks-A Systematic Survey of the Literature with Recommendations.Journal of Clinical Epidemiology,2017,82(1):4-11." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES2298AFD1BF6895B650DDF99FE1121B6A&amp;v=MDE1NzM5bTkyZnRFRnAwSkJIVTh2UkFXNmtzSlBuYnIybWMwZUxDVk43enVDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Rmh6THU5dzZ3PU5pZk9mYkc2Rg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[5]</b>
                                         Manja V,Albashir S,Guyatt G.Criteria for use of Composite Endpoints for Competing Risks-A Systematic Survey of the Literature with Recommendations.Journal of Clinical Epidemiology,2017,82(1):4-11.
                                    </a>
                                </li>
                                <li id="14">


                                    <a id="bibliography_6" title=" Anker SD,Schroeder S,Atar D,et al.Traditional and new composite endpoints in heart failure clinical trials:facilitating comprehensive efficacy assessments and improving trial efficiency.European Journal of Heart Failure,2016,18(5):482-489." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD38B4C4F51F5ECAE13E61DB7A7ED8CCE7&amp;v=Mjk2NjVicm5OcytZQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEZoekx1OXc2dz1OaWZjYXJDd2JOVy9xL2xBWlowS2VROUl1aGNRbnpsOFBBM2wzUlZBRA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[6]</b>
                                         Anker SD,Schroeder S,Atar D,et al.Traditional and new composite endpoints in heart failure clinical trials:facilitating comprehensive efficacy assessments and improving trial efficiency.European Journal of Heart Failure,2016,18(5):482-489.
                                    </a>
                                </li>
                                <li id="16">


                                    <a id="bibliography_7" title=" Rauch G,Rauch B,Kieser M,et al.Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.World Journal of Cardiology,2015,7(1):1-5." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=WJXZ201501001&amp;v=MTE5ODZxZlp1Wm5GeURtVWJ6TU1pZlRkTEc0SDlUTXJvOUZaWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjc=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                         Rauch G,Rauch B,Kieser M,et al.Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.World Journal of Cardiology,2015,7(1):1-5.
                                    </a>
                                </li>
                                <li id="18">


                                    <a id="bibliography_8" title=" Pocock SJ,WangD, Ariti C,et al.The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.European Heart Journal,2012,33(2):176-182." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities">
                                        <b>[8]</b>
                                         Pocock SJ,WangD, Ariti C,et al.The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.European Heart Journal,2012,33(2):176-182.
                                    </a>
                                </li>
                                <li id="20">


                                    <a id="bibliography_9" title=" Finkelstein DM,Schoenfeld DA.Combining mortality and longitudinal measures in clinical trials.Statistics in Medicine,1999,11(18):1341-1354." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00001269174&amp;v=MjUxNTVjYXJPNEh0SE5yWWxNWmV3TFkzazV6QmRoNGo5OVNYcVJyeG94Y01IN1I3cWRaK1p1RmlIbFc3ektJMW89Tmlm&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[9]</b>
                                         Finkelstein DM,Schoenfeld DA.Combining mortality and longitudinal measures in clinical trials.Statistics in Medicine,1999,11(18):1341-1354.
                                    </a>
                                </li>
                                <li id="22">


                                    <a id="bibliography_10" title=" XiaodongLuo,Hong Tian,Surya Mohanty,et al.An alternative approach to confidence interval estimation for the win ratio statistic.Biometrics,2015,71(1):139-145." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD15040200000320&amp;v=MDIzMjY5RlpPc1BEMzQ1b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmJJS0YwV2FSWT1OaWZjYXJLOUh0WE1yWQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[10]</b>
                                         XiaodongLuo,Hong Tian,Surya Mohanty,et al.An alternative approach to confidence interval estimation for the win ratio statistic.Biometrics,2015,71(1):139-145.
                                    </a>
                                </li>
                                <li id="24">


                                    <a id="bibliography_11" title=" X Luo,J Qiu,S Bai,et al.Weighted win loss approach for analyzing prioritized outcomes.Statistics in Medicine,2017,36(15):2452-2465." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD5FF7AD1D2E91FA530D9BDBF664ACA7B6&amp;v=MTgyNjJpWkNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRGaHpMdTl3Nnc9TmlmY2FyYk9hTmE5MjQ0eFpwNEdEUXBJeWhVVG5qWVBQQTJVcWhReENNSGxRcw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                         X Luo,J Qiu,S Bai,et al.Weighted win loss approach for analyzing prioritized outcomes.Statistics in Medicine,2017,36(15):2452-2465.
                                    </a>
                                </li>
                                <li id="26">


                                    <a id="bibliography_12" title=" Buyse M.Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.Statistics in Medicine,2010,29(30):3245-3257." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00001271379&amp;v=MjA5NTVoNGo5OVNYcVJyeG94Y01IN1I3cWRaK1p1RmlIbFc3ektJMW89TmlmY2FyTzRIdEhOclloRVord0dZM2s1ekJk&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[12]</b>
                                         Buyse M.Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.Statistics in Medicine,2010,29(30):3245-3257.
                                    </a>
                                </li>
                                <li id="28">


                                    <a id="bibliography_13" title=" Claggett B,Wei LJ,Pfeffer MA.Moving beyond our comfort zone.European Heart Journal,2013,34 (12):869-871." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Moving beyond our comfort zone">
                                        <b>[13]</b>
                                         Claggett B,Wei LJ,Pfeffer MA.Moving beyond our comfort zone.European Heart Journal,2013,34 (12):869-871.
                                    </a>
                                </li>
                                <li id="30">


                                    <a id="bibliography_14" title=" Montori VM,Guyatt GH.Validity of composite end points in clinical trials.BMJ,2005,330(7491):594-596." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJST&amp;filename=SJST14113000872644&amp;v=MDI2MDJ3TkNuZzlvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyYklLRjBXYVJZPU5pZlllcks4SDlEUHI0OUZiTw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[14]</b>
                                         Montori VM,Guyatt GH.Validity of composite end points in clinical trials.BMJ,2005,330(7491):594-596.
                                    </a>
                                </li>
                                <li id="32">


                                    <a id="bibliography_15" title=" Freemantle N,Calvert M,Wood J,et al.Composite outcomes in randomized trials:greater precision but with greater uncertainty.JAMA,2003,289(19):2554-2559." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Composite outcomes in randomized trials: greater precision but with greater uncertainty?">
                                        <b>[15]</b>
                                         Freemantle N,Calvert M,Wood J,et al.Composite outcomes in randomized trials:greater precision but with greater uncertainty.JAMA,2003,289(19):2554-2559.
                                    </a>
                                </li>
                                <li id="34">


                                    <a id="bibliography_16" title=" Ferreiragonz&#225;lez I,Permanyermiralda G,Busse JW,et al.Methodologic discussions for using and interpreting endpoints are limited,but still identify major concerns.Journal of Clinical Epidemiology,2007,60(7):651-657." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012300051245&amp;v=MDg4NTQ5RlpPNE9Ebmc4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmJJS0YwV2FSWT1OaWZPZmJLN0h0RE9ySQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[16]</b>
                                         Ferreiragonz&#225;lez I,Permanyermiralda G,Busse JW,et al.Methodologic discussions for using and interpreting endpoints are limited,but still identify major concerns.Journal of Clinical Epidemiology,2007,60(7):651-657.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=ZGWT" target="_blank">中国卫生统计</a>
                2019,36(04),497-501             </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm">基于赢率分析临床复合终点的统计方法</span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%97%AB%E4%BF%8A%E7%BA%A2&amp;code=42823060&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">闫俊红</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E6%9D%A8%E7%B4%AB%E8%8D%86&amp;code=41237015&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">杨紫荆</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E4%BE%AF%E9%9B%85%E6%96%87&amp;code=14036276&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">侯雅文</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%99%88%E5%BE%81&amp;code=23878101&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">陈征</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E5%8D%97%E6%96%B9%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E5%85%AC%E5%85%B1%E5%8D%AB%E7%94%9F%E5%AD%A6%E9%99%A2%E7%94%9F%E7%89%A9%E7%BB%9F%E8%AE%A1%E5%AD%A6%E7%B3%BB&amp;code=0060982&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">南方医科大学公共卫生学院生物统计学系</a>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E6%9A%A8%E5%8D%97%E5%A4%A7%E5%AD%A6%E7%BB%8F%E6%B5%8E%E5%AD%A6%E9%99%A2%E7%BB%9F%E8%AE%A1%E5%AD%A6%E7%B3%BB&amp;code=0182757&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">暨南大学经济学院统计学系</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p><b>目的</b> 当复合终点(事件)中组分结局事件的临床优先级问题存在时,传统基于风险比的方法常出现一定的估计误差。本文以急性淋巴细胞白血病患者预后研究为背景,讨论能解决该问题的统计方法。<b>方法</b> 介绍在组分事件之间的优先级非常重要时,一种新的指标赢率的概念和分析方法;随后将该方法应用于急性淋巴细胞白血病的预后研究,比较风险比和基于赢率的匹配、不匹配和加权赢率法的差异。<b>结果</b> 研究发现,赢率法显示GvHD预防是急性淋巴细胞白血病患者预后的危害因素,而风险比的结果与之相反,这是由于在含有多个优先级结局事件的研究中,风险比受第一结局事件的影响,结果往往存在一定的偏差,而赢率能更好的反映实际情况。<b>结论</b> 当组分事件之间的优先级很重要时,相对于风险比,赢率是一个更好的统计评价指标。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E7%94%9F%E5%AD%98%E5%88%86%E6%9E%90&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">生存分析;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">临床试验;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E5%A4%8D%E5%90%88%E7%BB%88%E7%82%B9&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">复合终点;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E9%A3%8E%E9%99%A9%E6%AF%94&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">风险比;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%B5%A2%E7%8E%87&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">赢率;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                                            </p>
                
                    <p>

                            <b>基金：</b>
                                                        <span>国家自然科学基金(81673268);</span>
                                <span>广东省自然科学基金(2017A030313812,2018A030313849);</span>
                                <span>南方医科大学大学生创新创业训练计划项目(201712121260);</span>
                    </p>
            </div>
                    <h1><b>A Win Ratio Approach to Comparing Composite Outcomes in Clinical Trials</b></h1>
                    <h2>
                    <span>Yan Junhong</span>
                    <span>Yang Zijing</span>
                    <span>Hou Yawen</span>
            </h2>
                    <h2>
                    <span>Department of Biostatistics,School of Public Health,Southern Medical University</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p><b>Objective</b> When the clinical priority of components in the composite endpoints exists,the hazard ratio often has some estimation errors.Based on the prognosis of patients with acute lymphoblastic leukemia,this study discusses the statistical methods that can solve this problem.<b>Methods</b> Firstly,we introduced the win ratio a new approach to the analysis of composite endpoints when the priority between components is important;this method was subsequently applied to the prognosis study of acute lymphoblastic leukemia,comparing the differences between the hazard ratio,the matched win ratio,the unmatched win ratio and the weighted win ratio.<b>Results</b> The win ratio showed that GvHD prevention was a risk factor for prognosis in patients with acute lymphoblastic leukemia,while the hazard ratio was the opposite.This is because in the study with multiple endpoints,the hazard ratio is influenced by the first event,which leads to deviations.However,the win ratio is not affected.<b>Conclusion</b> The win ratio is better statistical measure than the hazard ratio when the clinical priorities among components matters.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Survival%20analysis&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Survival analysis;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Clinical%20trials&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Clinical trials;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Composite%20endpoints&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Composite endpoints;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Hazard%20ratio&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Hazard ratio;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Win%20ratio&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Win ratio;</a>
                </p>
            </div>
        

        <!--brief start-->
                        <div class="p1">
                    <p id="36">急性淋巴细胞白血病是一类造血干细胞恶性克隆性疾病,其主要表现为外周血中出现异常的白细胞,失去控制后在骨髓和其他造血组织中大量增殖,导致正常红细胞和血小板的生成减少。急性淋巴细胞白血病自然病程较短,若不治疗,一般多在6个月内死亡。但经过骨髓移植治疗后的患者,也会出现复发、发生不良事件、死亡等结局事件<citation id="104" type="reference"><link href="4" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。这种由多个结局事件组合而成的终点称为复合终点(composite endpoints),常被用作随机临床试验的主要终点,以提高试验的效率<citation id="105" type="reference"><link href="6" rel="bibliography" /><link href="8" rel="bibliography" /><sup>[<a class="sup">2</a>,<a class="sup">3</a>]</sup></citation>。由于复合终点的事件发生率相对较高,较易发现组间差异,从而可以降低试验所需的样本量,减少研究时间和成本。另外,以复合终点作为主要终点,也可以避免多重性问题和竞争风险问题<citation id="106" type="reference"><link href="10" rel="bibliography" /><link href="12" rel="bibliography" /><sup>[<a class="sup">4</a>,<a class="sup">5</a>]</sup></citation>。但传统复合终点的应用也存在一定的局限,它通常将所有结局事件视为同等重要,并且只考虑最先发生的结局事件,如在急性淋巴细胞白血病的临床研究中,复合终点定义为患者死亡和发生不良事件,若患者首先发生不良事件,之后更为重要的该患者是否死亡就被忽略了,也就是说,早期发生的非致命事件比后来发生的更严重的事件具有更高的优先级。因此,当各终点事件对患者的重要性不一致时,对结果的解释变得尤为困难<citation id="107" type="reference"><link href="14" rel="bibliography" /><link href="16" rel="bibliography" /><sup>[<a class="sup">6</a>,<a class="sup">7</a>]</sup></citation>。</p>
                </div>
                <div class="p1">
                    <p id="37">为了解决上述问题,Pocock等人<citation id="108" type="reference"><link href="18" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>提出了“赢率”(win ratio)这一新指标或方法,它在传统复合终点的基础上将复合终点组成事件的临床优先级加以考虑,即根据研究目的及临床意义对组分结局事件的重要性进行排序,优先考虑重要性高的事件。本文将基于急性淋巴细胞白血病患者预后研究的实际数据,介绍赢率的定义、估计以及相应的统计推断方法,并将其与传统的风险比(hazard ratio,HR)进行比较。</p>
                </div>
                <h3 id="38" name="38" class="anchor-tag">资料与方法</h3>
                <h4 class="anchor-tag" id="39" name="39">1.研究对象</h4>
                <div class="p1">
                    <p id="40">选用1985年至1998年在欧洲血液和骨髓移植学会(EBMT)注册的2279例急性淋巴细胞白血病患者数据,所有患者均在初次完全缓解时进行亲缘供者异基因骨髓移植术。随访期间记录的事件包括:发生不良事件、血小板恢复、复发和死亡。这里的不良事件定义为在移植后100天内出现2级及其以上的移植物抗宿主病。预后信息包括:供受者性别匹配、GvHD预防、移植年份和移植年龄。</p>
                </div>
                <h4 class="anchor-tag" id="41" name="41">2.调查内容</h4>
                <div class="p1">
                    <p id="42">对GvHD预防的临床益处的进行评估,复合终点定义为患者死亡和发生不良事件,其中死亡具有较大的优先级,而其他状态作为右删失。</p>
                </div>
                <h4 class="anchor-tag" id="43" name="43">3.数据整理及分析</h4>
                <div class="p1">
                    <p id="44">应用R 3.4.3进行数据整理、基线信息描述以及模型建立和估计。</p>
                </div>
                <h4 class="anchor-tag" id="45" name="45">4.研究方法</h4>
                <div class="p1">
                    <p id="46">本研究运用3种赢率法来评估GvHD预防对急性淋巴细胞白血病治疗的临床益处。将进行GvHD预防的患者设为试验组,对照组由未进行GvHD预防的患者组成,根据患者的风险情况将两组患者进行两两配对,对于任一患者对(试验和对照组患者各一名),若试验组患者先发生终点事件,则该患者称为“失败者(loser)”,反之则这个试验组患者为“获胜者(winner)”。所有配对中获胜者总数与失败者总数之比即为赢率。若赢率等于1,则认为是平局,即两组疗效无差异;大于1时,认为试验组获胜,即试验组疗效更好,如赢率等于1.8,其含义是与对照组相比,试验组的获胜者多了80%。赢率包括未加权赢率(unweighted win ratio)和加权赢率(weighted win ratio),其中未加权赢率有两种计算方法,分别是匹配赢率法(matched win ratio)和不匹配赢率法(unmatched win ratio)。同时也应用传统<i>HR</i>的方法,与上述赢率的方法结果进行对比分析。</p>
                </div>
                <h4 class="anchor-tag" id="47" name="47">(1)匹配赢率</h4>
                <div class="p1">
                    <p id="48">匹配赢率法考虑到患者个体风险,根据试验组和对照组患者的风险值进行匹配。这里风险值的计算基于Cox比例风险模型<i>h</i>(<i>t</i>|<i>X</i>)=<i>h</i><sub>0</sub>(<i>t</i>)<i>exp</i>(<i>β</i><sub>1</sub><i>X</i><sub>1</sub>+<i>β</i><sub>2</sub><i>X</i><sub>2</sub>+…+<i>β</i><sub><i>k</i></sub><i>X</i><sub><i>k</i></sub>),其中<i>h</i>(<i>t</i>|<i>X</i>)是具有协变量<i>X</i>的个体在<i>t</i>时刻的风险函数,<i>t</i>为生存时间,<i>X</i>=(<i>X</i><sub>1</sub>,<i>X</i><sub>2</sub>,…,<i>X</i><sub><i>k</i></sub>)′是可能影响生存时间的有关因素,也称协变量。<i>h</i><sub>0</sub>(<i>t</i>)是基线风险函数,<i>β</i>=(<i>β</i><sub>1</sub>,<i>β</i><sub>2</sub>,…,<i>β</i><sub><i>k</i></sub>)′为模型的回归系数。根据该模型,计算出每个患者的个体风险值(=<i>β</i><sub>1</sub><i>X</i><sub>1</sub>+<i>β</i><sub>2</sub><i>X</i><sub>2</sub>+…+<i>β</i><sub><i>k</i></sub><i>X</i><sub><i>k</i></sub>)。若两组患者数量不等,则首先将样本量较大的组别的患者随机剔除,保证两组患者数相同。然后分别对试验组和对照组的患者进行风险值排序,两组中排序数相同的患者两两匹配。对每对患者首先研究优先重要事件(这里是患者死亡),主要观察谁最先发生该事件,若该结果无从得知,则观察谁先发生不良事件。图1说明了在每对患者中进行这种比较所涉及的步骤,可能有以下5种情况:</p>
                </div>
                <div class="p1">
                    <p id="49">①试验组患者先死亡;</p>
                </div>
                <div class="p1">
                    <p id="50">②对照组患者先死亡;</p>
                </div>
                <div class="p1">
                    <p id="51">③试验组患者先发生不良事件;</p>
                </div>
                <div class="p1">
                    <p id="52">④对照组患者先发生不良事件;</p>
                </div>
                <div class="p1">
                    <p id="53">⑤以上情况均未出现。</p>
                </div>
                <div class="area_img" id="54">
                                <a class="zoom-in" href="Detail/GetImg?filename=images/ZGWT201904005_054.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                    <img alt="图1 试验组和对照组患者的比较" src="Detail/GetImg?filename=images/ZGWT201904005_054.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
                                </a>
                                <p class="img_tit"><b>图1</b> 试验组和对照组患者的比较  <a class="btn-zoomin" href="Detail/GetImg?filename=images/ZGWT201904005_054.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!"></a><a class="downimg">&nbsp;&nbsp;下载原图</a></p>
                            <p class="img_tit"></p>

                </div>
                <div class="p1">
                    <p id="55">上述5种情况的对子数分别定义为<i>N</i><sub>1</sub>、<i>N</i><sub>2</sub>、<i>N</i><sub>3</sub>、<i>N</i><sub>4</sub>和<i>N</i><sub>5</sub>,则试验组的“获胜者”数量<i>N</i><sub><i>w</i></sub>为<i>N</i><sub><i>w</i></sub>=<i>N</i><sub>2</sub>+<i>N</i><sub>4</sub>,“失败者”的数量<i>N</i><sub><i>l</i></sub>为<i>N</i><sub><i>l</i></sub>=<i>N</i><sub>1</sub>+<i>N</i><sub>3</sub>。所以,赢率<i>R</i><sub><i>W</i></sub>定义为</p>
                </div>
                <div class="p1">
                    <p id="56" class="code-formula">
                        <mathml id="56"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>R</mi><msub><mrow></mrow><mi>W</mi></msub><mo>=</mo><mfrac><mrow><mi>Ν</mi><msub><mrow></mrow><mi>w</mi></msub></mrow><mrow><mi>Ν</mi><msub><mrow></mrow><mi>l</mi></msub></mrow></mfrac></mrow></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="57">此时,试验组“获胜者”所占的比率<i>P</i><sub><i>W</i></sub>为</p>
                </div>
                <div class="p1">
                    <p id="58" class="code-formula">
                        <mathml id="58"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo>=</mo><mfrac><mrow><mi>Ν</mi><msub><mrow></mrow><mi>w</mi></msub></mrow><mrow><mi>Ν</mi><msub><mrow></mrow><mi>w</mi></msub><mo>+</mo><mi>Ν</mi><msub><mrow></mrow><mi>l</mi></msub></mrow></mfrac></mrow></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="59">该比率<i>P</i><sub><i>W</i></sub>的95%可信区间是</p>
                </div>
                <div class="p1">
                    <p id="60" class="code-formula">
                        <mathml id="60"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo>±</mo><mn>1</mn><mo>.</mo><mn>9</mn><mn>6</mn><mrow><mo>[</mo><mrow><mfrac><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo stretchy="false">)</mo></mrow><mrow><mo stretchy="false">(</mo><mi>Ν</mi><msub><mrow></mrow><mi>w</mi></msub><mo>+</mo><mi>Ν</mi><msub><mrow></mrow><mi>l</mi></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow><mo>]</mo></mrow><msup><mrow></mrow><mrow><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow></msup><mo>=</mo><mi>Ρ</mi><msub><mrow></mrow><mi>L</mi></msub><mo>,</mo><mi>Ρ</mi><msub><mrow></mrow><mi>U</mi></msub></mrow></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="61">所以赢率的95%可信区间是</p>
                </div>
                <div class="p1">
                    <p id="62" class="code-formula">
                        <mathml id="62"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo stretchy="false">(</mo><mfrac><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>L</mi></msub></mrow><mrow><mn>1</mn><mo>-</mo><mi>Ρ</mi><msub><mrow></mrow><mi>L</mi></msub></mrow></mfrac><mo>,</mo><mfrac><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>U</mi></msub></mrow><mrow><mn>1</mn><mo>-</mo><mi>Ρ</mi><msub><mrow></mrow><mi>U</mi></msub></mrow></mfrac><mo stretchy="false">)</mo></mrow></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="63">两组比较时,对于原假设H<sub>0</sub>:<i>R</i><sub><i>W</i></sub>=1(试验组与对照组不存在差异),检验统计量<i>Z</i>服从渐近正态分布。</p>
                </div>
                <div class="p1">
                    <p id="64" class="code-formula">
                        <mathml id="64"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>Ζ</mi><mo>=</mo><mfrac><mrow><mo stretchy="false">(</mo><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo>-</mo><mn>0</mn><mo>.</mo><mn>5</mn><mo stretchy="false">)</mo></mrow><mrow><mrow><mo>[</mo><mrow><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Ρ</mi><msub><mrow></mrow><mi>W</mi></msub><mo stretchy="false">)</mo><mo>/</mo><mo stretchy="false">(</mo><mi>Ν</mi><msub><mrow></mrow><mi>w</mi></msub><mo>+</mo><mi>Ν</mi><msub><mrow></mrow><mi>l</mi></msub><mo stretchy="false">)</mo></mrow><mo>]</mo></mrow><msup><mrow></mrow><mrow><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow></msup></mrow></mfrac></mrow></math></mathml>
                    </p>
                </div>
                <h4 class="anchor-tag" id="65" name="65">(2)不匹配赢率</h4>
                <div class="p1">
                    <p id="66">匹配赢率法虽考虑了患者的个体风险值,但风险评分函数的选择具有一定的主观性,若两组患者的数量相差较大,会导致一大部分的患者被剔除,丧失生存信息。因此,可考虑使用不匹配赢率法,也就是不经过匹配,直接将试验组中的每位患者分别与对照组中的每位患者进行比较。如<i>N</i><sub><i>n</i></sub>和<i>N</i><sub><i>s</i></sub>分别代表试验组以及对照组的患者数,即要进行<i>N</i><sub><i>n</i></sub>×<i>N</i><sub><i>s</i></sub>次比较,每次同样可能出现上文所示的5种情况(图1)。此时赢率的计算虽然与匹配法相同,但其95%可信区间是基于bootstrap重采样构建的<citation id="109" type="reference"><link href="18" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>,组间比较的检验统计量基于Finkelstein和Schoenfeld的非参数方法<citation id="110" type="reference"><link href="20" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>计算得出,过程更为复杂。但bootstrap重采样需要大量的计算时间,且并未给出方差的闭式解,所得结果并不精确。为此,Luo等<citation id="111" type="reference"><link href="22" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>推导出了不匹配情况的赢率方差估计值的闭式解σ<mathml id="96"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><msubsup><mrow></mrow><mtext>R</mtext><mn>2</mn></msubsup></mrow></math></mathml>,同时为了提高效率,又在此基础上提出了加权赢率法<citation id="112" type="reference"><link href="24" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="67" name="67">(3)加权赢率</h4>
                <div class="p1">
                    <p id="68">设<i>T</i><sub><i>H</i></sub>和<i>T</i><sub><i>D</i></sub>是表示发生不良事件和死亡时间的两个随机变量,<i>T</i><sub><i>C</i></sub>代表删失的时间。<i>Y</i><sub>1</sub> =<i>T</i><sub><i>H</i></sub>^<i>T</i><sub><i>D</i></sub>^<i>T</i><sub><i>C</i></sub>和<i>Y</i><sub>2</sub> =<i>T</i><sub><i>D</i></sub>^<i>T</i><sub><i>C</i></sub>(^表示求最小值)。<i>δ</i><sub>1</sub>和<i>δ</i><sub>2</sub>分别为<i>Y</i><sub>1</sub>和<i>Y</i><sub>2</sub>的指示变量,如分别观察到不良事件或死亡,则对应<i>δ</i><sub>1</sub>=1或<i>δ</i><sub>2</sub>=1;否则,分别为<i>δ</i><sub>1</sub>=0或<i>δ</i><sub>2</sub>=0。观测数据(<i>Y</i><sub>1</sub><sub><i>i</i></sub>,<i>Y</i><sub>2</sub><sub><i>i</i></sub>,<i>δ</i><sub>1</sub><sub><i>i</i></sub>,<i>δ</i><sub>2</sub><sub><i>i</i></sub>,<i>M</i><sub><i>i</i></sub>),<i>i</i>=1,2…<i>n</i>,是(<i>Y</i><sub>1</sub>,<i>Y</i><sub>2</sub>,<i>δ</i><sub>1</sub>,<i>δ</i><sub>2</sub>,<i>M</i>)的独立同分布样本,其中<i>M</i>=1代表试验组,<i>M</i>=0代表对照组;<i>y</i><sub>1</sub>,<i>y</i><sub>2</sub>分别是该分布上<i>Y</i><sub>1</sub>,<i>Y</i><sub>2</sub>对应点的期望值。</p>
                </div>
                <div class="p1">
                    <p id="69">对于某一患者对,假设患者<i>j</i>来自对照组,患者<i>i</i>来自试验组。定义<i>W</i><sub>2</sub><sub><i>ij</i></sub>=<i>δ</i><sub>2</sub><sub><i>j</i></sub><i>I</i>(<i>Y</i><sub>2</sub><sub><i>i</i></sub>≥<i>Y</i><sub>2</sub><sub><i>j</i></sub>)以及<i>W</i><sub>1</sub><sub><i>ij</i></sub>=<i>δ</i><sub>1</sub><sub><i>j</i></sub><i>I</i>(<i>Y</i><sub>1</sub><sub><i>i</i></sub>≥<i>Y</i><sub>1</sub><sub><i>j</i></sub>)分别表示患者<i>i</i>在死亡事件和发生不良事件上“获胜”,<i>L</i><sub>2</sub><sub><i>ij</i></sub>=<i>δ</i><sub>2</sub><sub><i>i</i></sub><i>I</i>(<i>Y</i><sub>2</sub><sub><i>j</i></sub>≥<i>Y</i><sub>2</sub><sub><i>i</i></sub>)以及<i>L</i><sub>1</sub><sub><i>ij</i></sub>=<i>δ</i><sub>1</sub><sub><i>i</i></sub><i>I</i>(<i>Y</i><sub>1</sub><sub><i>j</i></sub>≥<i>Y</i><sub>1</sub><sub><i>i</i></sub>)则为“失败”的情况,因此“平局”分别为<i>Ω</i><sub>2</sub><sub><i>ij</i></sub>=(1-<i>W</i><sub>2</sub><sub><i>ij</i></sub>)(1-<i>L</i><sub>2</sub><sub><i>ij</i></sub>)以及<i>Ω</i><sub>1</sub><sub><i>ij</i></sub>=(1-<i>W</i><sub>1</sub><sub><i>ij</i></sub>)(1-<i>L</i><sub>1</sub><sub><i>ij</i></sub>)。表1给出了该指标变量组合的9种情况。其中,情况<i>W</i><sub>2</sub><sub><i>ij</i></sub><i>W</i><sub>1</sub><sub><i>ij</i></sub>、<i>W</i><sub>2</sub><sub><i>ij</i></sub><i>Ω</i><sub>1</sub><sub><i>ij</i></sub>、<i>W</i><sub>2</sub><sub><i>ij</i></sub><i>L</i><sub>1</sub><sub><i>ij</i></sub>以及<i>Ω</i><sub>2</sub><sub><i>ij</i></sub><i>W</i><sub>1</sub><sub><i>ij</i></sub>属于“获胜”,<i>Ω</i><sub>2</sub><sub><i>ij</i></sub><i>Ω</i><sub>1</sub><sub><i>ij</i></sub>属于平局,其余为“失败”。</p>
                </div>
                <div class="area_img" id="70">
                    <p class="img_tit"><b>表1</b> 输赢指标变量图 <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="70" border="1"><tr><td rowspan="2"><br /></td><td rowspan="2"></td><td colspan="3"><br />不良事件</td></tr><tr><td><br />赢</td><td>平</td><td>输</td></tr><tr><td><br /></td><td>赢</td><td><i>W</i><sub>2<i>ij</i></sub><i>W</i><sub>1<i>ij</i></sub></td><td><i>W</i><sub>2<i>ij</i></sub><i>Ω</i><sub>1<i>ij</i></sub></td><td><i>W</i><sub>2<i>ij</i></sub><i>L</i><sub>1<i>ij</i></sub></td></tr><tr><td><br />死亡</td><td>平</td><td><i>Ω</i><sub>2<i>ij</i></sub><i>W</i><sub>1<i>ij</i></sub></td><td><i>Ω</i><sub>2<i>ij</i></sub><i>Ω</i><sub>1<i>ij</i></sub></td><td><i>Ω</i><sub>2<i>ij</i></sub><i>L</i><sub>1<i>ij</i></sub></td></tr><tr><td><br /></td><td>输</td><td><i>L</i><sub>2<i>ij</i></sub><i>W</i><sub>1<i>ij</i></sub></td><td><i>L</i><sub>2<i>ij</i></sub><i>Ω</i><sub>1<i>ij</i></sub></td><td><i>L</i><sub>2<i>ij</i></sub><i>L</i><sub>1<i>ij</i></sub></td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note"></p>
                    <p class="img_note"></p>
                </div>
                <div class="p1">
                    <p id="71">设<i>G</i><sub>2</sub> (·)和<i>G</i><sub>1</sub> (·)分别是死亡与不良事件的加权函数,该加权函数可根据研究者的需要定义,通常取</p>
                </div>
                <div class="p1">
                    <p id="72" class="code-formula">
                        <mathml id="72"><math xmlns="http://www.w3.org/1998/Math/MathML"><mtable columnalign="left"><mtr><mtd><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>y</mi><mo stretchy="false">)</mo><mo>=</mo><mi>n</mi><msup><mrow></mrow><mrow><mo>-</mo><mn>1</mn></mrow></msup><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>k</mi><mo>=</mo><mn>0</mn></mrow><mn>1</mn></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mi>Ι</mi></mstyle></mrow></mstyle><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>≥</mo><mi>y</mi><msub><mrow></mrow><mn>2</mn></msub><mo>,</mo><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo>=</mo><mi>k</mi><mo stretchy="false">)</mo></mtd></mtr><mtr><mtd><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>y</mi><mo stretchy="false">)</mo><mo>=</mo><mi>n</mi><msup><mrow></mrow><mrow><mo>-</mo><mn>1</mn></mrow></msup><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>k</mi><mo>=</mo><mn>0</mn></mrow><mn>1</mn></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mi>Ι</mi></mstyle></mrow></mstyle></mtd></mtr></mtable></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="73">(<i>Y</i><sub>1</sub><sub><i>i</i></sub>≥<i>y</i><sub>1</sub>,<i>Y</i><sub>2</sub><sub><i>i</i></sub>≥<i>y</i><sub>2</sub>,<i>M</i><sub><i>i</i></sub>=<i>k</i>)</p>
                </div>
                <div class="p1">
                    <p id="74">则图1中①②③④的加权数分别为</p>
                </div>
                <div class="p1">
                    <p id="75" class="code-formula">
                        <mathml id="75"><math xmlns="http://www.w3.org/1998/Math/MathML"><mtable columnalign="left"><mtr><mtd><mi>L</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mfrac><mrow><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>L</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle></mrow></mstyle><mo>,</mo></mtd></mtr><mtr><mtd><mi>W</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mfrac><mrow><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>W</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle></mrow></mstyle></mtd></mtr><mtr><mtd><mi>L</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mfrac><mrow><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>Ω</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mi>L</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>j</mi></mrow></msub><mo>,</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle></mrow></mstyle><mo>,</mo></mtd></mtr><mtr><mtd><mi>W</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mfrac><mrow><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>Ω</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mi>W</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>j</mi></mrow></msub><mo>,</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle></mrow></mstyle></mtd></mtr></mtable></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="76">所以,加权赢差(weightedwin difference)<i>W</i><sub><i>D</i></sub><citation id="113" type="reference"><link href="26" rel="bibliography" /><sup>[<a class="sup">12</a>]</sup></citation>为</p>
                </div>
                <div class="p1">
                    <p id="77"><i>W</i><sub><i>D</i></sub>(<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>)={<i>W</i><sub>2</sub>(<i>G</i><sub>2</sub>)+<i>W</i><sub>1</sub>(<i>G</i><sub>1</sub>)}-{<i>L</i><sub>2</sub>(<i>G</i><sub>2</sub>)+<i>L</i><sub>1</sub>(<i>G</i><sub>1</sub>) }<mathml id="97"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mo>=</mo><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mrow><mstyle displaystyle="true"><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></munderover><mi>Μ</mi></mstyle></mrow></mstyle><msub><mrow></mrow><mi>i</mi></msub><mo stretchy="false">(</mo><mn>1</mn><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mo stretchy="false">{</mo><mfrac><mrow><mi>W</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mo>-</mo><mi>L</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac><mo>+</mo><mfrac><mrow><mi>Ω</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mo stretchy="false">(</mo><mi>W</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub><mo>-</mo><mi>L</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>j</mi></mrow></msub><mo>,</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac><mo stretchy="false">}</mo></mrow></math></mathml></p>
                </div>
                <div class="p1">
                    <p id="79">然后,加权赢率为</p>
                </div>
                <div class="p1">
                    <p id="80" class="code-formula">
                        <mathml id="80"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>W</mi><msub><mrow></mrow><mi>R</mi></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo>,</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mfrac><mrow><mi>W</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>+</mo><mi>W</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo></mrow><mrow><mi>L</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>+</mo><mi>L</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></math></mathml>
                    </p>
                </div>
                <div class="p1">
                    <p id="81">假设(<i>T</i><sub><i>H</i></sub>,<i>T</i><sub><i>D</i></sub>)的联合分布是连续的,<i>λ</i><sub><i>Dk</i></sub>(<i>y</i><sub>2</sub>)=<i>pr</i>(<i>T</i><sub><i>D</i></sub>=<i>y</i><sub>2</sub>|<i>T</i><sub><i>D</i></sub>≥<i>y</i><sub>2</sub>,<i>M</i>=<i>k</i>)为第<i>k</i>组的<i>T</i><sub><i>D</i></sub>的风险函数,<i>λ</i><sub><i>Hk</i></sub>(<i>y</i><sub>2</sub>|<i>y</i><sub>2</sub>)=<i>pr</i>(<i>T</i><sub><i>H</i></sub>=<i>y</i><sub>1</sub>|<i>T</i><sub><i>H</i></sub>≥<i>y</i><sub>1</sub>,<i>T</i><sub><i>D</i></sub>≥<i>y</i><sub>2</sub>,<i>M</i>=<i>k</i>)为第<i>k</i>组<i>T</i><sub><i>H</i></sub>的条件风险函数,<i>λ</i><sub><i>Ck</i></sub>(<i>y</i><sub>2</sub>)=<i>pr</i>(<i>T</i><sub><i>C</i></sub>=<i>y</i><sub>2</sub>|<i>T</i><sub><i>C</i></sub>≥<i>y</i><sub>2</sub>,<i>M</i>=<i>k</i>)为第<i>k</i>组<i>T</i><sub><i>C</i></sub>的风险函数,其中<i>k</i>=0,1。定义<i>λ</i><sub><i>CT</i></sub>(<i>y</i><sub>2</sub>)=<i>λ</i><sub><i>C</i></sub><sub>0</sub>(<i>y</i><sub>2</sub>)+<i>λ</i><sub><i>C</i></sub><sub>1</sub>(<i>y</i><sub>2</sub>)为删失的总风险函数。统计量<i>W</i><sub><i>D</i></sub> (<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>)可用于检验原假设H<sub>0</sub>:<i>W</i><sub><i>R</i></sub> (<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>)=1。这里原假设可分为两小部分H<sub>0</sub>=H<sub>01</sub>∩H<sub>02</sub></p>
                </div>
                <div class="p1">
                    <p id="82">H<sub>01</sub>:对于所有的<i>y</i><sub>2</sub>,<i>λ</i><sub><i>D</i></sub><sub>1</sub> (<i>y</i><sub>2</sub>)=<i>λ</i><sub><i>D</i></sub><sub>0</sub> (<i>y</i><sub>2</sub>),</p>
                </div>
                <div class="p1">
                    <p id="83">H<sub>02</sub>:对于所有的<i>y</i><sub>1</sub> ≤<i>y</i><sub>2</sub>,<i>λ</i><sub><i>H</i></sub><sub>1</sub> (<i>y</i><sub>1</sub> |<i>y</i><sub>2</sub>)=<i>λ</i><sub><i>H</i></sub><sub>0</sub> (<i>y</i><sub>1</sub> |<i>y</i><sub>2</sub>)。</p>
                </div>
                <div class="p1">
                    <p id="84">用<i>W</i><sub>2</sub> (<i>G</i><sub>2</sub>)-<i>L</i><sub>2</sub> (<i>G</i><sub>2</sub>)验证H<sub>01</sub>,用<i>W</i><sub>1</sub> (<i>G</i><sub>1</sub>)-<i>L</i><sub>1</sub> (<i>G</i><sub>1</sub>)验证H<sub>02</sub>,<i>W</i><sub><i>R</i></sub>值也可用于检验H<sub>0</sub>。如果新的治疗方法在延迟死亡或不良事件治疗方面有效,则原假设H<sub>0</sub>将被拒绝。对于加权赢差<i>W</i><sub><i>D</i></sub>(<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>),在原假设H<sub>0</sub>的条件下<i>n</i><sup>-3/2</sup><i>W</i><sub><i>D</i></sub>(<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>)～<i>N</i>(0,<i>σ</i><mathml id="98"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><msubsup><mrow></mrow><mi>D</mi><mn>2</mn></msubsup></mrow></math></mathml>)。其中<i>σ</i><sup>2</sup><sub><i>D</i></sub>=<mathml id="99"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>n</mi><msup><mrow></mrow><mrow><mo>-</mo><mn>1</mn></mrow></msup><mstyle displaystyle="true"><msubsup><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></msubsup><mo stretchy="false">(</mo></mstyle><mi>σ</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>+</mo><mi>σ</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo><mo stretchy="false">}</mo><msup><mrow></mrow><mn>2</mn></msup><mo>,</mo><mo stretchy="false">{</mo><mi>σ</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mfrac><mn>1</mn><mi>n</mi></mfrac><mstyle displaystyle="true"><msubsup><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></msubsup><mrow><mfrac><mrow><mo stretchy="false">(</mo><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>W</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mo>-</mo><mi>L</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle><mo>,</mo><mo stretchy="false">{</mo><mi>σ</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo><mo>=</mo><mfrac><mn>1</mn><mi>n</mi></mfrac><mstyle displaystyle="true"><msubsup><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>n</mi></msubsup><mrow><mfrac><mrow><mo stretchy="false">(</mo><mi>Μ</mi><msub><mrow></mrow><mi>i</mi></msub><mo>-</mo><mi>Μ</mi><msub><mrow></mrow><mi>j</mi></msub><mo stretchy="false">)</mo><mi>Ω</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi><mi>j</mi></mrow></msub><mo stretchy="false">(</mo><mi>W</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub><mo>-</mo><mi>L</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow><mrow><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>1</mn><mi>j</mi></mrow></msub><mo>,</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>i</mi></mrow></msub><mo>^</mo><mi>Y</mi><msub><mrow></mrow><mrow><mn>2</mn><mi>j</mi></mrow></msub><mo stretchy="false">)</mo></mrow></mfrac></mrow></mstyle></mrow></math></mathml>。</p>
                </div>
                <div class="p1">
                    <p id="85">则检验统计量为:<mathml id="100"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>Ζ</mi><mo>=</mo><mfrac><mrow><mi>n</mi><msup><mrow></mrow><mrow><mo>-</mo><mn>3</mn><mo>/</mo><mn>2</mn></mrow></msup><mi>W</mi><msub><mrow></mrow><mi>D</mi></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo>,</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo></mrow><mrow><mi>σ</mi><msub><mrow></mrow><mi>D</mi></msub></mrow></mfrac><mo>,</mo></mrow></math></mathml></p>
                </div>
                <div class="p1">
                    <p id="86"><i>Z</i>服从标准正态分布,对于加权赢率,有<mathml id="101"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>n</mi><msup><mrow></mrow><mrow><mfrac><mn>1</mn><mn>2</mn></mfrac></mrow></msup><mo stretchy="false">{</mo><mi>W</mi><msub><mrow></mrow><mi>R</mi></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo>,</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo><mo>-</mo><mn>1</mn><mo stretchy="false">}</mo><mo>∼</mo><mi>Ν</mi><mo stretchy="false">(</mo><mn>0</mn><mo>,</mo><mi>σ</mi><msubsup><mrow></mrow><mi>R</mi><mn>2</mn></msubsup><mo stretchy="false">)</mo></mrow></math></mathml>,其中<mathml id="102"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><mi>σ</mi><msubsup><mrow></mrow><mi>R</mi><mn>2</mn></msubsup><mo>=</mo><mi>σ</mi><msubsup><mrow></mrow><mi>D</mi><mn>2</mn></msubsup><mo stretchy="false">{</mo><mfrac><mrow><mi>L</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>2</mn></msub><mo stretchy="false">)</mo></mrow><mrow><mi>n</mi><msup><mrow></mrow><mn>2</mn></msup></mrow></mfrac><mo>+</mo><mfrac><mrow><mi>L</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">(</mo><mi>G</mi><msub><mrow></mrow><mn>1</mn></msub><mo stretchy="false">)</mo></mrow><mrow><mi>n</mi><msup><mrow></mrow><mn>2</mn></msup></mrow></mfrac><mo stretchy="false">}</mo><msup><mrow></mrow><mrow><mo>-</mo><mn>2</mn></mrow></msup></mrow></math></mathml>,其95%的置信区间为<i>exp</i>(<i>W</i><sub><i>R</i></sub>(<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>)±1.96<i>n</i><sup>-1/2</sup><i>σ</i><mathml id="103"><math xmlns="http://www.w3.org/1998/Math/MathML"><mrow><msubsup><mrow></mrow><mi>R</mi><mn>2</mn></msubsup></mrow></math></mathml>/<i>W</i><sub><i>R</i></sub>(<i>G</i><sub>1</sub>,<i>G</i><sub>2</sub>))。</p>
                </div>
                <h3 id="87" name="87" class="anchor-tag">结  果</h3>
                <div class="p1">
                    <p id="88">在纳入研究的2279例急性淋巴细胞白血病患者中,1496例患者在移植后发生复合终点事件,这其中有838例患者死亡。发生死亡事件的患者中位生存时间为3.64年,删失率约为63.2%;而发生复合终点事件的患者中位生存时间为0.14年,删失率约为34.4%。结合各变量的生存曲线图(图2)可发现,对于死亡事件(图2左侧),患者的累积生存率的下降相对较平缓;而对于复合终点事件(图2右侧),患者的累积生存率在随访开始阶段急剧下降,且最终都已小于50%。因为相较于死亡事件,患者不良事件的发生一般在随访前期。</p>
                </div>
                <div class="p1">
                    <p id="89">对于GvHD预防变量进行log-rank检验,死亡事件(图2E)下显示未进行GvHD预防的患者生存率较高(<i>χ</i><sup>2</sup>=11.8,<i>P</i>&lt;0.001),而复合终点(图2F)给出相反的结论(<i>χ</i><sup>2</sup>=4.6,<i>P</i>=0.03)。为探究该现象的原因,对GvHD预防进行临床益处的评估,见表2。对于匹配赢率法,在549对匹配患者对中,“获胜者”为未预防组的患者先死亡106对或者先发生不良事件100对,“失败者”则为预防组的患者先死亡211对或者先发生不良事件56对,共473对(86.16%)患者发生复合终点事件,这反映进行GvHD预防的患者可能有相对较差的预后。相应的赢率值为0.772(<i>Z</i>=2.829,<i>P</i>=0.002),这表示接受GvHD预防的患者的预后情况不如未接受GvHD预防的患者。不匹配赢率法比较每位接受GvHD预防与未接受GvHD预防的患者,所以共有1730×549 = 949770个患者对,其中825108对(86.87%)患者发生复合终点事件,复合终点的不匹配赢率为0.938(<i>Z</i>=0.994,<i>P</i>=0.320),虽小于1,但无统计学意义(<i>Z</i>=0.994,<i>P</i>=0.320),95%置信区间也包含1。加权赢率法通过对图1中①～④四种情况的患者数进行加权,所得数量均比未匹配赢率法大,其复合终点的赢率为0.792,有统计学意义(<i>Z</i>=3.390,<i>P</i>&lt;0.001),且<i>P</i>值较前两种赢率更小,即更有把握认为GvHD预防是有害因素。对于风险比指标,当仅对死亡事件分析时,<i>HR</i>大于1(<i>Z</i>=11.710,<i>P</i>&lt;0.001)表示GvHD预防是危险因素;而复合终点的<i>HR</i>小于1(<i>Z</i>=4.550,<i>P</i>=0.033),表明GvHD预防是保护因素。因不良事件往往先发生,所以GvHD预防对死亡率的影响会在复合终点的分析中部分丧失。</p>
                </div>
                <div class="area_img" id="90">
                                <a class="zoom-in" href="Detail/GetImg?filename=images/ZGWT201904005_090.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                    <img alt="图2 各变量生存曲线图" src="Detail/GetImg?filename=images/ZGWT201904005_090.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
                                </a>
                                <p class="img_tit"><b>图2</b> 各变量生存曲线图  <a class="btn-zoomin" href="Detail/GetImg?filename=images/ZGWT201904005_090.jpg&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!"></a><a class="downimg">&nbsp;&nbsp;下载原图</a></p>
                            <p class="img_tit"></p>

                </div>
                <div class="area_img" id="91">
                    <p class="img_tit"><b>表2</b> GvHD预防临床益处的评估 <a class="downexcel" onclick="DownLoadReportExcel(this)">导出到EXCEL</a></p>
                    <p class="img_tit"></p>
                    <p class="img_note"></p>
                    <table id="91" border="1"><tr><td><br /></td><td>匹配赢率</td><td>不匹配赢率</td><td>加权赢率</td><td><i>HR</i><sup>†</sup></td><td><i>HR</i><sup>*</sup></td></tr><tr><td><br />①预防组先死亡</td><td>211</td><td>317970</td><td>416261.78</td><td>/</td><td>/</td></tr><tr><td><br />②未预防组先死亡</td><td>106</td><td>246454</td><td>320357.62</td><td>/</td><td>/</td></tr><tr><td><br />③预防组先发生严重不良事件</td><td>56</td><td>107762</td><td>36596.18</td><td>/</td><td>/</td></tr><tr><td><br />④未预防组先发生严重不良事件</td><td>100</td><td>152922</td><td>38073.29</td><td>/</td><td>/</td></tr><tr><td><br />⑤以上均不是</td><td>76</td><td>124662</td><td>/</td><td>/</td><td>/</td></tr><tr><td><br />总对数</td><td>549</td><td>949770</td><td>/</td><td>/</td><td>/</td></tr><tr><td><br />点估计</td><td>0.772</td><td>0.938</td><td>0.792</td><td>1.300</td><td>0.878</td></tr><tr><td><br />95% <i>CI</i></td><td>(0.642,0.924)</td><td>(0.827,1.064)</td><td>(0.667,0.939)</td><td>(1.118,1.51)</td><td>(0.779,0.990)</td></tr><tr><td><br />统计量<i>Z</i></td><td>2.829</td><td>0.994</td><td>3.390</td><td>11.710</td><td>4.550</td></tr><tr><td><br /><i>P</i>值</td><td>0.002</td><td>0.320</td><td>&lt;0.001</td><td>&lt;0.001</td><td>0.033</td></tr></table>
                    <form name="form" action="/kxreader/Detail/DownloadReportExcel" method="POST" style="display:inline">
                        <input type="hidden" name="hidTable" value="" />
                        <input type="hidden" name="hidFileName" value="" />
                    </form>
                    <p class="img_note">†:死亡事件的风险比;*:复合事件的风险比。</p>
                    <p class="img_note"></p>
                </div>
                <h3 id="92" name="92" class="anchor-tag">讨  论</h3>
                <div class="p1">
                    <p id="93">随机对照临床试验是目前测试治疗策略是否会改变特定结局事件的金标准。为了测试这一假设,研究人员需要建立一个详细的统计分析计划,以测定两种(或更多)治疗策略之间观察到的差异是否归因于偶然性<citation id="114" type="reference"><link href="28" rel="bibliography" /><sup>[<a class="sup">13</a>]</sup></citation>。当主要终点是死亡,而且问题的关注点在于干预是否改变了患者的生存时间时,传统的统计框架提供了一个较好的处理方式。但除非目标人群限于那些预后极差的患者,否则主要终点为死亡的试验很少进行。一个设计良好的临床试验前瞻性地将复合终点植入其主要分析计划中,以便观测到干预措施极小的影响。然而在随机试验中,复合终点的广泛使用引发了关于其适用性和结果解释的争议<citation id="115" type="reference"><link href="30" rel="bibliography" /><link href="32" rel="bibliography" /><link href="34" rel="bibliography" /><sup>[<a class="sup">14</a>,<a class="sup">15</a>,<a class="sup">16</a>]</sup></citation>。</p>
                </div>
                <div class="p1">
                    <p id="94">本文共介绍了3种赢率法,当两组患者数量均衡时,匹配赢率法考虑患者自身的风险因素,能较好的估计干预因素对复合终点的作用,但是若两组患者的数量相差较大,会导致一大部分的患者被剔除,丧失生存信息,不匹配赢率法以及加权赢率法能弥补这一缺点。当样本量很大时,不匹配赢率法可信区间的估计较为费时,加权赢率法能较快的给出结果。</p>
                </div>
                <div class="p1">
                    <p id="95">结合本文实例分析结果,复合终点的3种赢率均小于1,显示GvHD预防是危害因素(虽不匹配赢率法无统计学意义),这是因为GvHD预防通常是采用去除T细胞(TCD)的方法,该法虽可减轻GvHD,但却减弱了移植物的抗白血病作用,可增加感染和死亡率。当采用赢率法进行分析时,该法给予死亡事件更大的优先级,因此“GvHD预防增加死亡率”这一弊端被展现出来。而传统方法分析的<i>HR</i>将复合终点中的组分事件予以相同的重要性,但不良事件往往发生于死亡事件之前,因此死亡事件往往被忽略,这就导致复合终点的<i>HR</i>=0.878(<i>Z</i>=4.550,<i>P</i>=0.033),给出GvHD预防是保护因素的错误结论。因此,建议在非致命事件较常见的临床研究中,当组分事件之间的优先级很重要时,使用加权赢率法来进行分析,而不是采用风险比的方法。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="4">
                            <a id="bibliography_1" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Marrow transplantation for patients with acute lymphoblastic leukemia in remission">

                                <b>[1]</b> Thomas ED,Sanders JE,Flournoy N,et al.Marrow transplantation for patients with acute lymphoblastic leukemia in remission.Blood,1979,54 (2):467.
                            </a>
                        </p>
                        <p id="6">
                            <a id="bibliography_2" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Introduction to Composite Endpoints">

                                <b>[2]</b> Moyé LA.Introduction to Composite Endpoints.Publications of the American Statistical Association,2007,100 (472):1463.
                            </a>
                        </p>
                        <p id="8">
                            <a id="bibliography_3" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SCUD&amp;filename=SCUD15062400106572&amp;v=MzEzNTU5SHRmT3E0OUZaZXNKQ1hzN29CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJiSUtGMFdhUlk9Tmk3ZWFySw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[3]</b> PavlovicM,Teljeur C,Wieseler B,et al.Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.International Journal of Technology Assessment in Health Care,2014,30 (5):508-513.
                            </a>
                        </p>
                        <p id="10">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD14011600000546&amp;v=MDgxMjhyUmRHZXJxUVRNbndaZVp0RmlubFVyYklLRjBXYVJZPU5pZmNhcks4SHRETnFZOUZaT3NQQ1hnL29CTVQ2VDRQUUgvaQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b> Alosh M,Bretz F,Huque M.Advanced multiplicity adjustment methods in clinical trials.Statistics in Medicine,2014,33(4):693-713.
                            </a>
                        </p>
                        <p id="12">
                            <a id="bibliography_5" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES2298AFD1BF6895B650DDF99FE1121B6A&amp;v=MTQyNzdwMEpCSFU4dlJBVzZrc0pQbmJyMm1jMGVMQ1ZON3p1Q09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEZoekx1OXc2dz1OaWZPZmJHNkY5bTkyZnRFRg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[5]</b> Manja V,Albashir S,Guyatt G.Criteria for use of Composite Endpoints for Competing Risks-A Systematic Survey of the Literature with Recommendations.Journal of Clinical Epidemiology,2017,82(1):4-11.
                            </a>
                        </p>
                        <p id="14">
                            <a id="bibliography_6" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD38B4C4F51F5ECAE13E61DB7A7ED8CCE7&amp;v=Mjc2ODk2dz1OaWZjYXJDd2JOVy9xL2xBWlowS2VROUl1aGNRbnpsOFBBM2wzUlZBRGJybk5zK1lDT052RlNpV1dyN0pJRnBtYUJ1SFlmT0dRbGZCckxVMDV0Rmh6THU5dw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[6]</b> Anker SD,Schroeder S,Atar D,et al.Traditional and new composite endpoints in heart failure clinical trials:facilitating comprehensive efficacy assessments and improving trial efficiency.European Journal of Heart Failure,2016,18(5):482-489.
                            </a>
                        </p>
                        <p id="16">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=WJXZ201501001&amp;v=MjQwMTlLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm5GeURtVWJ6TU1pZlRkTEc0SDlUTXJvOUZaWVE=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b> Rauch G,Rauch B,Kieser M,et al.Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.World Journal of Cardiology,2015,7(1):1-5.
                            </a>
                        </p>
                        <p id="18">
                            <a id="bibliography_8" target="_blank" href="http://scholar.cnki.net/result.aspx?q=The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities">

                                <b>[8]</b> Pocock SJ,WangD, Ariti C,et al.The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.European Heart Journal,2012,33(2):176-182.
                            </a>
                        </p>
                        <p id="20">
                            <a id="bibliography_9" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00001269174&amp;v=MDQwMzZhck80SHRITnJZbE1aZXdMWTNrNXpCZGg0ajk5U1hxUnJ4b3hjTUg3UjdxZForWnVGaUhsVzd6S0kxbz1OaWZj&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[9]</b> Finkelstein DM,Schoenfeld DA.Combining mortality and longitudinal measures in clinical trials.Statistics in Medicine,1999,11(18):1341-1354.
                            </a>
                        </p>
                        <p id="22">
                            <a id="bibliography_10" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD15040200000320&amp;v=MDI3NzZVcmJJS0YwV2FSWT1OaWZjYXJLOUh0WE1yWTlGWk9zUEQzNDVvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[10]</b> XiaodongLuo,Hong Tian,Surya Mohanty,et al.An alternative approach to confidence interval estimation for the win ratio statistic.Biometrics,2015,71(1):139-145.
                            </a>
                        </p>
                        <p id="24">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD5FF7AD1D2E91FA530D9BDBF664ACA7B6&amp;v=MTM3ODFsZkJyTFUwNXRGaHpMdTl3Nnc9TmlmY2FyYk9hTmE5MjQ0eFpwNEdEUXBJeWhVVG5qWVBQQTJVcWhReENNSGxRc2laQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b> X Luo,J Qiu,S Bai,et al.Weighted win loss approach for analyzing prioritized outcomes.Statistics in Medicine,2017,36(15):2452-2465.
                            </a>
                        </p>
                        <p id="26">
                            <a id="bibliography_12" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD00001271379&amp;v=MTMxNTA5OVNYcVJyeG94Y01IN1I3cWRaK1p1RmlIbFc3ektJMW89TmlmY2FyTzRIdEhOclloRVord0dZM2s1ekJkaDRq&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[12]</b> Buyse M.Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.Statistics in Medicine,2010,29(30):3245-3257.
                            </a>
                        </p>
                        <p id="28">
                            <a id="bibliography_13" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Moving beyond our comfort zone">

                                <b>[13]</b> Claggett B,Wei LJ,Pfeffer MA.Moving beyond our comfort zone.European Heart Journal,2013,34 (12):869-871.
                            </a>
                        </p>
                        <p id="30">
                            <a id="bibliography_14" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJST&amp;filename=SJST14113000872644&amp;v=MDE0NjFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyYklLRjBXYVJZPU5pZlllcks4SDlEUHI0OUZiT3dOQ25nOW9CTVQ2VDRQUQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[14]</b> Montori VM,Guyatt GH.Validity of composite end points in clinical trials.BMJ,2005,330(7491):594-596.
                            </a>
                        </p>
                        <p id="32">
                            <a id="bibliography_15" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Composite outcomes in randomized trials: greater precision but with greater uncertainty?">

                                <b>[15]</b> Freemantle N,Calvert M,Wood J,et al.Composite outcomes in randomized trials:greater precision but with greater uncertainty.JAMA,2003,289(19):2554-2559.
                            </a>
                        </p>
                        <p id="34">
                            <a id="bibliography_16" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012300051245&amp;v=MDY3OTBiSUtGMFdhUlk9TmlmT2ZiSzdIdERPckk5RlpPNE9Ebmc4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[16]</b> Ferreiragonzález I,Permanyermiralda G,Busse JW,et al.Methodologic discussions for using and interpreting endpoints are limited,but still identify major concerns.Journal of Clinical Epidemiology,2007,60(7):651-657.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="ZGWT201904005" />
        <input id="dpi" type="hidden" value="300" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>

    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=ZGWT201904005&amp;v=MTc1MzZZWVFLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm5GeURtVWJ6TVB5cmNlckc0SDlqTXE0OUY=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRsbWlROEJvNUc5VFdtU3JEQUFDdz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>

</body>
</html>
